Michael Altermatt retweeted
Our work on #MitoCatch, a system for targeted delivery of healthy mitochondria to specific cell types is now published in @Nature.
Very grateful to the team and collaborators, especially the first authors, @AyupovTemurkhan, @v_moreno_juan.
📄 Read more: nature.com/articles/s41586-0…
ALT Targeted mitochondrial delivery: Caption: Extracellular donor mitochondria are delivered specifically to neurons via bispecific protein binders.
Michael Altermatt retweeted
Excited to share that our technology for cell-type-targeted mitochondrial delivery is published in @Nature.
In this work, we introduce MitoCatch, a platform that enables programmable, targeted delivery of donor mitochondria to specific cell types. (1/7)
nature.com/articles/s41586-0…
Michael Altermatt retweeted
I am very happy to share that our paper is now published in @Nature 😊
Cell-type-targeted mitochondrial transplantation rescues cell degeneration.
nature.com/articles/s41586-0…
@IOB_ch (1/6)
Michael Altermatt retweeted
🎉 Thrilled to share our latest preprint! We conducted a large-scale screen with ~20,000 human retinal organoids, testing 2,707 compounds to counter cone-degeneration. Thanks to @IOB_Roska and my collaborators. 🧵👇 biorxiv.org/content/10.1101/…
Michael Altermatt retweeted
I just realized I never tweeted the release of the main paper behind my PhD work 😅, where @AltermattMi, @cosmotat, and I developed a method to characterize which cells get targeted by AAV gene therapy vectors. So, a few months behind, here it is: frontiersin.org/articles/10.… 1/6
The preprint of my third PhD research project is now available:
Deep parallel characterization of AAV tropism and AAV-mediated transcriptional changes via single-cell RNA sequencing biorxiv.org/content/10.1101/…
Michael Altermatt retweeted
We are hiring! Looking for talented people to join our fast-growing team as we work to create a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Visit capsida.com/#careers
Thrilled to read in today’s biotech news that former coworkers successfully secured Series A financing for their startup. Congrats Capsida!
With a stealth launch comes Capsida Biotherapeutics Inc., though there’s nothing under-the-radar about its hefty financing fiercebiotech.com/biotech/14…
Michael Altermatt retweeted
Applications welcome for a PhD position at the interface of neuroscience and machine learning, in Switzerland. iob.ch/jobs-view-all?tx_news…
Michael Altermatt retweeted
iSeroSnFR is a new fluorescent reporter for serotonin from @LinTianLab that allow the optical detection of millisecond-scale serotonin transients.
hubs.ly/H0F5Nb70
ALT Rounds of modeling and site-saturated mutagenesis resulted in iSeroSnFR which can be used as a serotonin sensor in mice and in vitro.
Michael Altermatt retweeted
Now available from @Addgene !
iSeroSnFR is a new fluorescent reporter for serotonin from @LinTianLab that allow the optical detection of millisecond-scale serotonin transients.
hubs.ly/H0F67TM0
ALT Rounds of modeling and site-saturated mutagenesis resulted in iSeroSnFR which can be used as a serotonin sensor in mice and in vitro.
Michael Altermatt retweeted
Here we used machine learning to guide directed evolution to design and radically change the ligand binding pocket for sensor engineering. Excellent team work with @LoogerL, @VivianGradinaru, @superkash, @vyy_sf! (1 of 2)
sciencedirect.com/science/ar…
Michael Altermatt retweeted
I am beyond excited to finally be able to share this with the world: a genetically encoded, highly selective, large dynamic range SEROTONIN SENSOR. authors.elsevier.com/c/1cFWe…
Michael Altermatt retweeted
Designer Proteins as Better Therapies: David Baker on The Long Run. @UWproteindesign timmermanreport.com/2019/12/…
